id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-269051-nl0jfqxt	Patel, Krish	Use of the IL‐6R Antagonist Tocilizumab in Hospitalized COVID‐19 Patients	2020-08-03		.txt	text/plain	1922	108	55	Baseline patient demographic and clinical characteristics including severity of COVID-19 illness using the Chinese CDC definition were recorded up to 10 days prior to anti-cytokine therapy. Survival and clinical outcomes were assessed for 42 tocilizumab-treated patients and 41 matched controls for whom at least 7 days of follow-up data were available or who had been discharged or died before 7 days following administration of tocilizumab or the corresponding time for the matched controls. The median time from hospitalization to receipt of tocilizumab therapy was 4 days (IQR, 4) and similar between severely and critically ill patients. At last follow-up 15 (71.4%) severely ill patients have been discharged, 4 (19.0%) died, with 2 (9.5%) remaining hospitalized ( Figure 1G ). In this retrospective cohort study, we report on use of tocilizumab in the treatment of severely and critically ill hospitalized COVID-19 patients.	./cache/cord-269051-nl0jfqxt.txt	./txt/cord-269051-nl0jfqxt.txt